Discover 2,503 paid clinical trials in Illinois. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Illinois offers various clinical research options, including those for healthy volunteers interested in paid studies, as well as for individuals with specific health conditions. Leading research centers in Chicago, Plainfield, and Springfield are actively seeking participants, providing access to innovative treatments and personalized care.
Filter
1
Filter results
Results: 2,503
Active & Responsive
Cortical Recording and Stimulating Array Brain-Machine Interface
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
for
Advanced or Metastatic Solid Tumors, Breast Cancer,
Location: 21 recruiting locations
Sponsor: IDEAYA Biosciences
Sex: All
Age: 18+
Code: NCT05787587
Phase1, Recruiting
Active & Responsive
A Study of RSLV-132 in Females With Sjögren's Disease
for
Primary Sjögren Syndrome
Location: 23 recruiting locations
Sponsor: Resolve Therapeutics
Sex: Female
Age: 18 - 70+
Code: NCT06440525
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
for
Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Location: 90 recruiting locations
Sponsor: Cleerly, Inc.
Sex: All
Age: 55+
Code: NCT06112418
Recruiting
Active & Responsive
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
for
Peripheral Artery Disease, Overweight or Obesity
Location: 4 recruiting locations
Sponsor: Northwestern University
Sex: All
Age: 18+
Code: NCT04228978
Recruiting
Active & Responsive
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer